Found 53 results in Expert Content

Abstract: Selling CDMO services is a complex task that calls for broad skill and technical depth.

Summary:​ Drug development today is shaped by 2 forces: the technical challenge of formulating complex molecules and the external challenge of navigating unstable global supply chains.

Summary: Late-stage scaling of spray drying for inhaled formulations can result in avoidable delays, post-approval issues, and cost overruns.

Summary: Inhalation powders have been used for decades to treat lung diseases and conditions requiring rapid systemic therapy.

Developers of innovative drug products dealing with protein formulations, nucleotide-based drugs, peptides, and poorly soluble molecules, face significant challenges in achieving efficient and scalable manufacturing solutions.

Developers of innovative drug products dealing with protein formulations, nucleotide-based drugs, peptides, and poorly soluble molecules, face significant challenges in achieving efficient and scalable manufacturing solutions.

Summary: This article provides an in-depth review of milling equipment, including jet, pin, hammer, conical, and cryogenic mills.

Nasal development is an attractive option but can be difficult, requiring expertise to overcome formulation challenges, and to navigate the complexities of drug/device combination products to optimize drug delivery.

Summary: Originally published in Inhalation magazine, this article discusses how nasal powder formulations represent a significant stride in drug delivery innovation. With drug developers and approvers evolving to address the unique considerations of nasal drug delivery, nasal powders offer a robust and adaptable platform in the pharmaceutical landscape.

Summary: In this article, Dr. Alan Watts, Director of Innovation & Partnerships for Orally Inhaled Products at Catalent, and Michael Tauber, Senior Director of Pharmaceutical Development at Acorda Therapeutics discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.